跳至主要内容
MedPath Trial logoMedPath TrialMedPath Trial Home
临床试验/NCT00144339
NCT00144339已完成3 期

A Randomized, Double-blind, Placebo-controlled, Parallel Group Trial Assessing the Rate of Decline of Lung Function With Tiotropium 18 mcg Inhalation Capsule Once Daily in Patients With Chronic Obstructive Pulmonary Disease (COPD).

Boehringer Ingelheim490 个研究点 分布在 1 个国家目标入组 5,993 人开始时间: 2002年12月1日最近更新:
Share to TwitterShare to FacebookShare to LinkedInShare to Reddit
适应症
相关药物

试验速览

阶段
3 期
状态
已完成
入组人数
5,993
试验地点
490
主要终点
Pre-bronchodilator Forced Expiratory Volume in One Second (FEV1) Rate of Decline From Day 30 to 4 Years
研究概览研究设计入排标准结局指标研究者研究点记录与标识符相似试验

研究概览

简要总结

The primary objective of this trial is to determine whether daily treatment with tiotropium (Spiriva®, Bromuro de Tiotropio®) inhalation capsule via HandiHaler® reduces the rate of decline in lung function over time in patients with COPD.

研究设计

研究类型
Interventional
干预模型
Parallel
主要目的
Treatment

入排标准

年龄范围
40 Years 至 —（Adult, Older Adult）
性别
All
接受健康志愿者
否

入选标准

  • •Written informed consent.
  • •Male or female patients 40 years of age or older.
  • •Smoking history of at least 10 pack years.
  • •Diagnosis of COPD with post bronchodilator FEV1 less than or equal to 70% of predicted normal and FEV1<70% of FVC and on stable respiratory medication.

排除标准

  • •Significant diseases other than COPD which in the opinion of the investigator may put the patient at risk or influence the patients ability to participate.
  • •Myocardial infarction in past 6 months.
  • •Unstable or life threatening arrhythmia in past year.
  • •Hospitalization for NYHA heart failure class III or IV in past year.
  • •Active tuberculosis.
  • •Pulmonary resection.
  • •Malignancy treated with radiation or chemotherapy in past 5 years.
  • •Respiratory infection in 4 weeks prior to screening.
  • •Known hypersensitivity to anticholinergic drugs or components.
  • •Known moderate to severe renal impairment.
  • •Known narrow angle glaucoma.
  • •Significant symptomatic BPH or bladder neck obstruction.
  • •Need for oxygen therapy >12 hr/day.
  • •Use of oral corticosteroids at unstable doses or >10 mg/day.

结局指标

主要结局

Pre-bronchodilator Forced Expiratory Volume in One Second (FEV1) Rate of Decline From Day 30 to 4 Years

时间窗: From day 30 to 4 years

Rate of decline of forced expiratory volume in one second (FEV1) measured before the use of bronchodilators. A negative rate of decline indicates decreasing FEV1 over time, while a positive value indicates increasing FEV1.

Post-bronchodilator Forced Expiratory Volume in One Second (FEV1) Rate of Decline From Day 30 to 4 Years

时间窗: From day 30 to 4 years

Rate of decline of forced expiratory volume in one second (FEV1) measured after bronchodilation. A negative rate of decline indicates decreasing FEV1 over time, while a positive value indicates increasing FEV1.

次要结局

  • Pre-bronchodilator Forced Expiratory Volume in One Second (FEV1) Rate of Decline From Day 1 to 30 Days After Completion of Double Blinded Treatment(Day 1 to 30 days after completion of double blinded treatment between Day 1 and 4 years plus 30 days.)
  • Pre-bronchodilator Forced Vital Capacity (FVC) Rate of Decline From Day 30 to 4 Years(From day 30 to 4 years)
  • Time to First Exacerbation(From Day 1 to 4 years)
  • Estimated Post-bronchodilator Forced Vital Capacity (FVC) at Month 12(Month 12)
  • Estimated Pre-bronchodilator Forced Vital Capacity (FVC) at Month 18(Month 18)
  • Post-bronchodilator Forced Expiratory Volume in One Second (FEV1) Rate of Decline From Day 1 to 30 Days After Completion of Double Blinded Treatment(Day 1 to 30 days after completion of double blinded treatment between Day 1 and 4 years plus 30 days)
  • Post-bronchodilator Forced Vital Capacity (FVC) Rate of Decline From Day 30 to 4 Years(From day 30 to 4 years)
  • Pre-bronchodilator Slow Vital Capacity (SVC) Rate of Decline From Day 30 to 4 Years(From day 30 to 4 years)
  • Post-bronchodilator Slow Vital Capacity (SVC) Rate of Decline From Day 30 to 4 Years(From day 30 to 4 years)
  • Rate of Decline of St George's Respiratory Questionnaire (SGRQ) Total Score(From month 6 to 4 years)
  • Pre-bronchodilator Forced Vital Capacity (FVC) Rate of Decline From Day 1 to 30 Days After Completion of Double Blinded Treatment(Day 1 to 30 days after completion of double blinded treatment between Day 1 and 4 years plus 30 days.)
  • Post-bronchodilator Forced Vital Capacity (FVC) Rate of Decline From Day 1 to 30 Days After Completion of Double Blinded Treatment(Day 1 to 30 days after completion of double blinded treatment between Day 1 and 4 years plus 30 days)
  • Pre-bronchodilator Slow Vital Capacity (SVC) Rate of Decline From Day 1 to 30 Days After Completion of Double Blinded Treatment(Day 1 to 30 days after completion of double blinded treatment between Day 1 and 4 years plus 30 days)
  • Post-bronchodilator Slow Vital Capacity (SVC) Rate of Decline From Day 1 to 30 Days After Completion of Double Blinded Treatment(Day 1 to 30 days after completion of double blinded treatment between Day 1 and 4 years plus 30 days)
  • Number of Chronic Obstructive Pulmonary Disease (COPD) Exacerbations Per Patient Year(Day 1 to 4 years)
  • Number and Percentage of Patients With at Least One Chronic Obstructive Pulmonary Disease (COPD) Exacerbation(Day 1 to 4 years)
  • Number of Exacerbation Days Per Patient Year(Day 1 to 4 years)
  • Time to First COPD Exacerbation Leading to Hospitalization (for 25% Patients)(Day 1 to 4 years)
  • Number and Percentage of Patients With at Least on COPD Exacerbation Leading to Hospitalization(From Day 1 to 4 years)
  • Number of Exacerbation Leading to Hospitalization(From Day 1 to 4 years)
  • Days of Chronic Obstructive Pulmonary Disease (COPD) Exacerbation Leading to Hospitalization(From Day 1 to 4 years)
  • Estimated Pre-bronchodilator Forced Expiratory Volume in One Second (FEV1) at Month 1(Month 1)
  • Estimated Post-bronchodilator Forced Expiratory Volume in One Second (FEV1) at Month 1(Month 1)
  • Estimated Pre-bronchodilator Forced Expiratory Volume in One Second (FEV1) at Month 6(Month 6)
  • Estimated Post-bronchodilator Forced Expiratory Volume in One Second (FEV1) at Month 6(Month 6)
  • Estimated Pre-bronchodilator Forced Expiratory Volume in One Second (FEV1) at Month 12(Month 12)
  • Estimated Post-bronchodilator Forced Expiratory Volume in One Second (FEV1) at Month 12(Month 12)
  • Estimated Pre-bronchodilator Forced Expiratory Volume in One Second (FEV1) at Month 18(Month 18)
  • Estimated Post-bronchodilator Forced Expiratory Volume in One Second (FEV1) at Month 18(Month 18)
  • Estimated Pre-bronchodilator Forced Expiratory Volume in One Second (FEV1) at Month 24(Month 24)
  • Estimated Post-bronchodilator Forced Expiratory Volume in One Second (FEV1) at Month 24(Month 24)
  • Estimated Pre-bronchodilator Forced Expiratory Volume in One Second (FEV1) at Month 30(Month 30)
  • Estimated Post-bronchodilator Forced Expiratory Volume in One Second (FEV1) at Month 30(Month 30)
  • Estimated Pre-bronchodilator Forced Expiratory Volume in One Second (FEV1) at Month 36(Month 36)
  • Estimated Post-bronchodilator Forced Expiratory Volume in One Second (FEV1) at Month 36(Month 36)
  • Estimated Pre-bronchodilator Forced Expiratory Volume in One Second (FEV1) at Month 42(Month 42)
  • Estimated Post-bronchodilator Forced Expiratory Volume in One Second (FEV1) at Month 42(Month 42)
  • Estimated Pre-bronchodilator Forced Expiratory Volume in One Second (FEV1) at Month 48(Month 48)
  • Estimated Post-bronchodilator Forced Expiratory Volume in One Second (FEV1) at Month 48(Month 48)
  • Estimated Pre-bronchodilator Forced Vital Capacity (FVC) at Month 1(Month 1)
  • Estimated Post-bronchodilator Forced Vital Capacity (FVC) at Month 1(Month 1)
  • Estimated Pre-bronchodilator Forced Vital Capacity (FVC) at Month 6(Month 6)
  • Estimated Post-bronchodilator Forced Vital Capacity (FVC) at Month 6(Month 6)
  • Estimated Pre-bronchodilator Forced Vital Capacity (FVC) at Month 12(Month 12)
  • Estimated Post-bronchodilator Forced Vital Capacity (FVC) at Month 18(Month 18)
  • Estimated Pre-bronchodilator Forced Vital Capacity (FVC) at Month 24(Month 24)
  • Estimated Post-bronchodilator Forced Vital Capacity (FVC) at Month 24(Month 24)
  • Estimated Pre-bronchodilator Forced Vital Capacity (FVC) at Month 30(Month 30)
  • Estimated Post-bronchodilator Forced Vital Capacity (FVC) at Month 30(Month 30)
  • Estimated Pre-bronchodilator Forced Vital Capacity (FVC) at Month 36(Month 36)
  • Estimated Post-bronchodilator Forced Vital Capacity (FVC) at Month 36(Month 36)
  • Estimated Pre-bronchodilator Forced Vital Capacity (FVC) at Month 42(Month 42)
  • Estimated Post-bronchodilator Forced Vital Capacity (FVC) at Month 42(Month 42)
  • Estimated Pre-bronchodilator Forced Vital Capacity (FVC) at Month 48(Month 48)
  • Estimated Post-bronchodilator Forced Vital Capacity (FVC) at Month 48(Month 48)
  • Estimated Pre-bronchodilator Slow Vital Capacity (SVC) at Month 1(Month 1)
  • Estimated Pre-bronchodilator Slow Vital Capacity (SVC) at Month 6(Month 6)
  • Estimated Pre-bronchodilator Slow Vital Capacity (SVC) at Month 30(Month 30)
  • Estimated Post-bronchodilator Slow Vital Capacity (SVC) at Month 36(Month 36)
  • Estimated St George's Respiratory Questionnaire (SGRQ) Total Score at Month 12(Month 12)
  • Estimated Post-bronchodilator Slow Vital Capacity (SVC) at Month 1(Month 1)
  • Estimated Pre-bronchodilator Slow Vital Capacity (SVC) at Month 24(Month 24)
  • Estimated Post-bronchodilator Slow Vital Capacity (SVC) at Month 24(Month 24)
  • Estimated Post-bronchodilator Slow Vital Capacity (SVC) at Month 6(Month 6)
  • Estimated Pre-bronchodilator Slow Vital Capacity (SVC) at Month 12(Month 12)
  • Estimated Post-bronchodilator Slow Vital Capacity (SVC) at Month 12(Month 12)
  • Estimated Pre-bronchodilator Slow Vital Capacity (SVC) at Month 18(Month 18)
  • Estimated Post-bronchodilator Slow Vital Capacity (SVC) at Month 18(Month 18)
  • Estimated Post-bronchodilator Slow Vital Capacity (SVC) at Month 30(Month 30)
  • Estimated Pre-bronchodilator Slow Vital Capacity (SVC) at Month 36(Month 36)
  • Estimated Pre-bronchodilator Slow Vital Capacity (SVC) at Month 42(Month 42)
  • Estimated Post-bronchodilator Slow Vital Capacity (SVC) at Month 42(Month 42)
  • Estimated Pre-bronchodilator Slow Vital Capacity (SVC) at Month 48(Month 48)
  • Estimated Post-bronchodilator Slow Vital Capacity (SVC) at Month 48(Month 48)
  • Estimated St George's Respiratory Questionnaire (SGRQ) Total Score at Month 6(Month 6)
  • Estimated St George's Respiratory Questionnaire (SGRQ) Total Score at Month 18(Month 18)
  • Estimated St George's Respiratory Questionnaire (SGRQ) Total Score at Month 24(Month 24)
  • Estimated St George's Respiratory Questionnaire (SGRQ) Total Score at Month 30(Month 30)
  • Estimated St George's Respiratory Questionnaire (SGRQ) Total Score at Month 36(Month 36)
  • Estimated St George's Respiratory Questionnaire (SGRQ) Total Score at Month 42(Month 42)
  • Estimated St George's Respiratory Questionnaire (SGRQ) Total Score at Month 48(Month 48)
  • Number and Percentage of Participants With All Cause Death and Time to Event Analysis (On-treatment)(Day 1 to completion of double blinded treatment plus 30 days between Day 1 and 4 years plus 30 days)
  • Number and Percentage of Participants With All Cause Death (Including Vital Status Follow-up, Cutoff at 1470 Days)(Day 1 to day 1470)
  • Number and Percentage of Participants With Lower Respiratory Death (On-treatment; Adjudicated Primary Cause)(Day 1 to completion of double blinded treatment plus 30 days between Day 1 and 4 years plus 30 days)
  • Number and Percentage of Participants With a Lower Respiratory Death (Adjudicated; Including Vital Status Follow-up, Cutoff at 1470 Days)(Day 1 to day 1470)

研究者

申办方类型
Industry

研究点 (490)

Loading locations...

相似试验

已完成
3 期
Tiotropium (18 Mcg) Once Daily Via the HandiHaler® in Patients With Chronic Obstructive Pulmonary Disease (COPD)Pulmonary Disease, Chronic Obstructive
NCT00274547Boehringer Ingelheim1,829
已完成
2 期
An Efficacy and Safety Evaluation of Tiotropium add-on Therapy in Patients With Severe Persistent AsthmaAsthma
NCT00365560Boehringer Ingelheim115
已完成
3 期
Efficacy and Safety Comparison of Tiotropium Daily + Salmeterol Daily or Twice Daily Versus Tiotropium Daily in Patients With COPDPulmonary Disease, Chronic Obstructive
NCT00662792Boehringer Ingelheim147
已完成
2 期
Efficacy and Safety of 3 Doses of Tiotropium Compared to Placebo in Adolescents (12 to 17 Yrs) With Moderate AsthmaAsthma
NCT01122680Boehringer Ingelheim105
已完成
3 期
Effect of Tiotropium Inhalation Capsules (Spiriva) on Exercise Tolerance in COPD PatientsPulmonary Disease, Chronic Obstructive
NCT00157235Boehringer Ingelheim234